Nortech Systems Earnings Call Transcripts
Fiscal Year 2026
-
Net sales grew 9.3% year-over-year to $33.5 million, with gross margin up to 17% and a strong backlog supporting future growth. Medical device and imaging segments led gains, while supply chain and tariff risks persist. Investments in innovation and AI position the company for continued momentum.
-
Q1 2026 saw strong year-over-year growth in sales, gross margin, and backlog, led by aerospace and defense. Strategic restructuring and new financing improved profitability and positioned the company for continued momentum, despite tariff and geopolitical uncertainties.
-
The meeting covered board elections, executive compensation, and approval of the 2026 Equity Incentive Plan, with all proposals passing. No questions were raised, and attendees were invited to a forthcoming earnings call for business updates.
Fiscal Year 2025
-
Third consecutive quarter of positive operating and EBITDA results, with improved gross margins and a 17.4% increase in backlog. Net sales declined 7.6% for the year, but Q4 sales and adjusted EBITDA showed strong year-over-year gains. Optimism for 2026 remains high.
-
Q3 2025 saw improved gross margin and adjusted EBITDA, despite a year-over-year sales decline driven by lower aerospace and defense revenue. Strong backlog, operational efficiencies, and new certifications support optimism for continued growth into 2026.
-
Q2 2025 saw lower revenue but improved earnings and positive EBITDA, driven by cost discipline and operational efficiencies. Aerospace and defense segment is expected to recover in H2 2025, with innovation in fiber optics and nearshoring strategies positioning the company for future growth.
-
Q1 2025 saw a 21.4% revenue decline due to customer delays and facility transitions, with gross margin dropping to 11.1%. Despite near-term headwinds, backlog stabilized and innovation in fiber optics positions the company for long-term growth.
Fiscal Year 2024
-
Net sales and profitability declined year-over-year due to customer order delays, inventory reductions, and facility transitions, with additional restructuring costs incurred. Strategic investments in leadership, innovation, and facility optimization are expected to drive long-term growth and operational efficiency.
-
Q3 2024 saw a decline in sales and margins due to customer order delays and market softness, especially in industrial and medical segments, while aerospace and defense showed growth. Facility consolidations and investments are expected to drive long-term savings and growth.
-
Q2 2024 saw a 3.2% year-over-year sales decline, with medical and industrial softness offset by strong aerospace and defense growth. Facility consolidation and new fiber optic products position the company for long-term savings and innovation-driven momentum.